X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with VENUS REMEDIES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs VENUS REMEDIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA VENUS REMEDIES AJANTA PHARMA/
VENUS REMEDIES
 
P/E (TTM) x 20.9 -819.1 - View Chart
P/BV x 9.1 0.2 3,777.7% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 AJANTA PHARMA   VENUS REMEDIES
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
VENUS REMEDIES
Mar-16
AJANTA PHARMA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,720218 789.0%   
Low Rs1,10382 1,343.5%   
Sales per share (Unadj.) Rs194.6365.6 53.2%  
Earnings per share (Unadj.) Rs45.21.5 3,043.0%  
Cash flow per share (Unadj.) Rs50.337.9 132.6%  
Dividends per share (Unadj.) Rs8.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs132.0382.5 34.5%  
Shares outstanding (eoy) m88.7711.44 776.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.30.4 1,767.3%   
Avg P/E ratio x31.2101.0 30.9%  
P/CF ratio (eoy) x28.14.0 709.2%  
Price / Book Value ratio x10.70.4 2,725.4%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m125,2991,717 7,299.4%   
No. of employees `000NA1.0 0.0%   
Total wages/salary Rs m2,570324 792.2%   
Avg. sales/employee Rs ThNM4,100.7-  
Avg. wages/employee Rs ThNM318.0-  
Avg. net profit/employee Rs ThNM16.7-  
INCOME DATA
Net Sales Rs m17,2754,183 413.0%  
Other income Rs m16620 827.4%   
Total revenues Rs m17,4424,203 415.0%   
Gross profit Rs m5,807812 715.5%  
Depreciation Rs m451417 108.1%   
Interest Rs m49380 12.9%   
Profit before tax Rs m5,47435 15,595.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,46018 8,065.7%   
Profit after tax Rs m4,01417 23,612.4%  
Gross profit margin %33.619.4 173.2%  
Effective tax rate %26.751.6 51.7%   
Net profit margin %23.20.4 5,717.0%  
BALANCE SHEET DATA
Current assets Rs m7,6392,771 275.7%   
Current liabilities Rs m2,7151,931 140.6%   
Net working cap to sales %28.520.1 142.0%  
Current ratio x2.81.4 196.1%  
Inventory Days Days43125 34.6%  
Debtors Days Days7954 146.4%  
Net fixed assets Rs m6,9145,328 129.8%   
Share capital Rs m177114 154.6%   
"Free" reserves Rs m11,4424,177 273.9%   
Net worth Rs m11,7214,376 267.8%   
Long term debt Rs m1491,911 7.8%   
Total assets Rs m14,8148,428 175.8%  
Interest coverage x112.91.1 10,338.8%   
Debt to equity ratio x00.4 2.9%  
Sales to assets ratio x1.20.5 235.0%   
Return on assets %27.44.7 582.5%  
Return on equity %34.20.4 8,816.4%  
Return on capital %46.56.6 705.1%  
Exports to sales %55.10-   
Imports to sales %6.020.5 29.3%   
Exports (fob) Rs m9,527NA-   
Imports (cif) Rs m1,038858 120.9%   
Fx inflow Rs m10,4220-   
Fx outflow Rs m1,678858 195.5%   
Net fx Rs m8,744-858 -1,018.7%   
CASH FLOW
From Operations Rs m3,264469 696.2%  
From Investments Rs m-2,09329 -7,167.5%  
From Financial Activity Rs m-1,186-464 255.8%  
Net Cashflow Rs m-1535 -42.9%  

Share Holding

Indian Promoters % 73.8 32.9 224.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 0.2 861.1%  
FIIs % 7.6 0.6 1,310.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 66.4 25.6%  
Shareholders   20,968 20,121 104.2%  
Pledged promoter(s) holding % 4.4 36.4 12.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   ORCHID PHARMA LTD  WYETH LTD  ABBOTT INDIA  UNICHEM LAB  CIPLA  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS